Skip to main content
Erschienen in: Annals of Hematology 1/2019

06.07.2018 | Letter to the Editor

Long-term remission of refractory Rosai-Dorfman disease after salvage therapy with clofarabine in an adult patient

verfasst von: Clemens Hinterleitner, Martina Steurer, Daniela Dörfel, Jonas Heitmann, Klaus-Peter Kreisselmeier, Karin Müller, Hans-Georg Kopp, Stefan Wirths, Michael Haap, Leticia Quintanilla-Martinez de Fend, Marius Horger, Carlos Rodriguez-Galindo, Lothar Kanz, Martin R. Müller

Erschienen in: Annals of Hematology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …
Literatur
1.
Zurück zum Zitat Rosai J, Dorfman RF (1969) Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. Arch Pathol 87(1):63–70PubMed Rosai J, Dorfman RF (1969) Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. Arch Pathol 87(1):63–70PubMed
2.
Zurück zum Zitat Foucar E, Rosai J, Dorfman R (1990) Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol 7(1):19–73PubMed Foucar E, Rosai J, Dorfman R (1990) Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol 7(1):19–73PubMed
3.
Zurück zum Zitat Cai Y, Shi Z, Bai Y (2017) Review of Rosai-Dorfman disease: new insights into the pathogenesis of this rare disorder. Acta Haematol 138(1):14–23CrossRefPubMed Cai Y, Shi Z, Bai Y (2017) Review of Rosai-Dorfman disease: new insights into the pathogenesis of this rare disorder. Acta Haematol 138(1):14–23CrossRefPubMed
4.
Zurück zum Zitat Jacobsen E, Shanmugam V, Jagannathan J (2017) Rosai-Dorfman disease with activating KRAS mutation—response to cobimetinib. N Engl J Med 377(24):2398–2399CrossRefPubMed Jacobsen E, Shanmugam V, Jagannathan J (2017) Rosai-Dorfman disease with activating KRAS mutation—response to cobimetinib. N Engl J Med 377(24):2398–2399CrossRefPubMed
5.
Zurück zum Zitat Oka M et al (2009) Successful treatment of Rosai-Dorfman disease with low-dose oral corticosteroid. J Dermatol 36(4):237–240CrossRefPubMed Oka M et al (2009) Successful treatment of Rosai-Dorfman disease with low-dose oral corticosteroid. J Dermatol 36(4):237–240CrossRefPubMed
6.
Zurück zum Zitat Dalia S, Sagatys E, Sokol L, Kubal T (2014) Rosai-Dorfman disease: tumor biology, clinical features, pathology, and treatment. Cancer Control 21(4):322–327CrossRefPubMed Dalia S, Sagatys E, Sokol L, Kubal T (2014) Rosai-Dorfman disease: tumor biology, clinical features, pathology, and treatment. Cancer Control 21(4):322–327CrossRefPubMed
7.
Zurück zum Zitat Zhao M, Li C, Zheng J, Yu J, Sha H, Yan M, Jin J, Sun K, Wang Z (2013) Extranodal Rosai-Dorfman disease involving appendix and mesenteric nodes with a protracted course: report of a rare case lacking relationship to IgG4-related disease and review of the literature. Int J Clin Exp Pathol 6(11):2569–2577PubMedPubMedCentral Zhao M, Li C, Zheng J, Yu J, Sha H, Yan M, Jin J, Sun K, Wang Z (2013) Extranodal Rosai-Dorfman disease involving appendix and mesenteric nodes with a protracted course: report of a rare case lacking relationship to IgG4-related disease and review of the literature. Int J Clin Exp Pathol 6(11):2569–2577PubMedPubMedCentral
8.
Zurück zum Zitat Scheel MM, Rady PL, Tyring SK, Pandya AG (1997) Sinus histiocytosis with massive lymphadenopathy: presentation as giant granuloma annulare and detection of human herpesvirus 6. J Am Acad Dermatol 37(4):643–646CrossRefPubMed Scheel MM, Rady PL, Tyring SK, Pandya AG (1997) Sinus histiocytosis with massive lymphadenopathy: presentation as giant granuloma annulare and detection of human herpesvirus 6. J Am Acad Dermatol 37(4):643–646CrossRefPubMed
9.
Zurück zum Zitat Pagel JM, Lionberger J, Gopal AK, Sabath DE, Loeb K (2007) Therapeutic use of rituximab for sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). Am J Hematol 82(12):1121–1122CrossRefPubMed Pagel JM, Lionberger J, Gopal AK, Sabath DE, Loeb K (2007) Therapeutic use of rituximab for sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). Am J Hematol 82(12):1121–1122CrossRefPubMed
10.
Zurück zum Zitat Lohr HF et al (1995) Long-term survival in a patient with Rosai-Dorfman disease treated with interferon-alpha. Eur J Cancer 31a(13–14):2427–2428CrossRefPubMed Lohr HF et al (1995) Long-term survival in a patient with Rosai-Dorfman disease treated with interferon-alpha. Eur J Cancer 31a(13–14):2427–2428CrossRefPubMed
11.
Zurück zum Zitat Maia RC, de Meis E, Romano S, Dobbin JA, Klumb CE (2015) Rosai-Dorfman disease: a report of eight cases in a tertiary care center and a review of the literature. Braz J Med Biol Res 48(1):6–12CrossRefPubMed Maia RC, de Meis E, Romano S, Dobbin JA, Klumb CE (2015) Rosai-Dorfman disease: a report of eight cases in a tertiary care center and a review of the literature. Braz J Med Biol Res 48(1):6–12CrossRefPubMed
12.
Zurück zum Zitat Cao XX, Sun J, Li J, Zhong DR, Niu N, Duan MH, Liang ZY, Zhou DB (2016) Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults. Ann Hematol 95(5):745–750CrossRefPubMed Cao XX, Sun J, Li J, Zhong DR, Niu N, Duan MH, Liang ZY, Zhou DB (2016) Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults. Ann Hematol 95(5):745–750CrossRefPubMed
13.
Zurück zum Zitat Go H, Jeon YK, Huh J, Choi SJ, Choi YD, Cha HJ, Kim HJ, Park G, Min S, Kim JE (2014) Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology 65(2):261–272CrossRefPubMed Go H, Jeon YK, Huh J, Choi SJ, Choi YD, Cha HJ, Kim HJ, Park G, Min S, Kim JE (2014) Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology 65(2):261–272CrossRefPubMed
14.
Zurück zum Zitat Simko SJ, Tran HD, Jones J, Bilgi M, Beaupin LK, Coulter D, Garrington T, McCavit TL, Moore C, Rivera-Ortegón F, Shaffer L, Stork L, Turcotte L, Welsh EC, Hicks MJ, McClain KL, Allen CE (2014) Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer 61(3):479–487CrossRefPubMed Simko SJ, Tran HD, Jones J, Bilgi M, Beaupin LK, Coulter D, Garrington T, McCavit TL, Moore C, Rivera-Ortegón F, Shaffer L, Stork L, Turcotte L, Welsh EC, Hicks MJ, McClain KL, Allen CE (2014) Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer 61(3):479–487CrossRefPubMed
15.
Zurück zum Zitat Eckstein O, Bingham R, Peckham EC, Brown A, Allen CE, McClain KL (2016) Efficacy and toxicity profile of clofarabine in patients with recurrent/refractory Langerhans cell histiocytosis and other histiocytic disorders. Blood 128:1329CrossRef Eckstein O, Bingham R, Peckham EC, Brown A, Allen CE, McClain KL (2016) Efficacy and toxicity profile of clofarabine in patients with recurrent/refractory Langerhans cell histiocytosis and other histiocytic disorders. Blood 128:1329CrossRef
Metadaten
Titel
Long-term remission of refractory Rosai-Dorfman disease after salvage therapy with clofarabine in an adult patient
verfasst von
Clemens Hinterleitner
Martina Steurer
Daniela Dörfel
Jonas Heitmann
Klaus-Peter Kreisselmeier
Karin Müller
Hans-Georg Kopp
Stefan Wirths
Michael Haap
Leticia Quintanilla-Martinez de Fend
Marius Horger
Carlos Rodriguez-Galindo
Lothar Kanz
Martin R. Müller
Publikationsdatum
06.07.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 1/2019
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-018-3421-7

Weitere Artikel der Ausgabe 1/2019

Annals of Hematology 1/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.